drugset / Trial / NCT05048134
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety and tolerability of HRS2300 and combined with SHR-1316 or SHR-1701 or trametinib or Almonertinib.To Determine the maximum tolerated dose (MTD) and recommended Dose (RP2D) for HRS2300 monotherapy and combination therapy.
Timeline
- Start
- 2021-10-25
- Primary completion
- 2023-02-24
- Completion
- 2023-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Almonertinib | Small molecule | — | — |
| Subject | HRS2300 | Unknown | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |
| Subject | Trametinib | Small molecule | — | — |